Fulgent Genetics (NASDAQ:FLGT) Issues Earnings Results

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) released its earnings results on Friday. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.22, Briefing.com reports. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The business had revenue of $73.46 million for the quarter, compared to the consensus estimate of $71.26 million. During the same period last year, the firm posted ($0.01) earnings per share. The firm's quarterly revenue was up 14.0% compared to the same quarter last year. Fulgent Genetics updated its FY 2025 guidance to -0.650--0.65 EPS.

Fulgent Genetics Price Performance

FLGT traded up $0.10 during midday trading on Thursday, hitting $18.75. 254,618 shares of the company's stock traded hands, compared to its average volume of 414,000. The company has a market cap of $578.74 million, a PE ratio of -3.40 and a beta of 1.00. Fulgent Genetics has a one year low of $14.57 and a one year high of $25.11. The stock's fifty day simple moving average is $17.66 and its 200-day simple moving average is $18.07.

Insider Transactions at Fulgent Genetics

In other news, CFO Paul Kim purchased 100,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the transaction, the chief financial officer now directly owns 348,282 shares in the company, valued at $5,558,580.72. This trade represents a 40.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.11% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Piper Sandler reaffirmed a "neutral" rating and issued a $23.00 price objective (up previously from $16.00) on shares of Fulgent Genetics in a research note on Tuesday. Raymond James reiterated an "outperform" rating and issued a $25.00 target price (up previously from $24.00) on shares of Fulgent Genetics in a research report on Monday. Finally, StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.